Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer - a podcast by American Society of Clinical Oncology (ASCO)

Dr. David Jackman of Dana-Farber Cancer Institute discusses how after introduction of a clinical pathway in metastatic NSCLC, cost of care decreased significantly with no compromise in survival.

Further episodes of JCO Oncology Practice Podcast

Further podcasts by American Society of Clinical Oncology (ASCO)

Website of American Society of Clinical Oncology (ASCO)